What DFE Pharma does

DFE Pharma GmbH & Co. KG is a German-headquartered, privately held supplier of pharmaceutical and nutraceutical excipients, organized as a limited partnership under German law with wholly-owned operating subsidiaries in Germany (HQ in Goch), the United States, India, Japan, and China. The company develops, produces, and supplies functional excipients — primarily lactose variants (milled, spray-dried, granulated, anhydrous, micronized), cellulose-based ingredients (microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate), co-processed multifunctional excipients, and high-purity sugars (BioHale Sucrose and Trehalose Dihydrate) — that serve as fillers, binders, disintegrants, and stabilizers in oral solid dose, inhalation, biopharmaceutical, and nutraceutical formulations. The BioHale portfolio specifically targets biologics stabilization, with documented use in COVID-19 vaccines, and conforms to ICH Q7 guidelines alongside the European, US, Japanese, and Chinese Pharmacopoeias. Manufacturing is supported by FDA-inspected facilities and a brand heritage described as exceeding 100 years.

The company operates a direct B2B sales model combining field sales representatives, an inside sales team accessible through 'Request a Quote' and 'Request a Sample' website forms, and an 'Ask an Expert' technical consultation channel. Customer segments span Biopharmaceutical Companies, Inhalation Drug Developers (DPI), Oral Solid Dose Manufacturers, and Nutraceutical Companies, with pricing conducted on a quote basis rather than published rates. DFE Pharma self-identifies as a 'global leader' in pharma- and nutraceutical excipient solutions. In February 2026, the company launched a Continuous Manufacturing Platform in collaboration with Gericke, hosted at its C2F Center of Excellence in Hyderabad, India, extending its offering from excipient supply into formulation development and process optimization services aligned with ICH Q13 guidelines. CVC Capital Partners participated in a 2019 funding round, indicating institutional investor backing for ongoing expansion.

Name

DFE Pharma

Legal name

DFE Pharma GmbH & Co. KG

Website

https://dfepharma.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

251–500 employees

Short description

DFE Pharma is a German-headquartered, global supplier of pharmaceutical and nutraceutical excipients — including lactose, microcrystalline cellulose, and high-purity sugars — serving biopharmaceutical, inhalation, oral solid dose, and nutraceutical manufacturers across Europe, the Americas, and Asia.

Ownership category

akta.pro rank

Product category

Pharmaceutical Excipients

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Pharmaceutical excipients
• Lactose excipient supply
• Biopharmaceutical stabilizers
• Dry powder inhaler lactose
• Oral solid dose excipients

Headquarters

HQ city

Goch

HQ country

Germany

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Excipient Sales: DFE Pharma generates revenue through the development, production, and supply of high-quality functional excipients for pharmaceutical and nutraceutical applications. The company sells directly to pharmaceutical manufacturers via a B2B model using direct sales teams, inside sales, and website-based quote/sample request processes. Products span multiple dosage forms including oral solid dose, inhalation, biopharma, and nutraceuticals.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

DFE Pharma develops, produces, and supplies functional pharmaceutical and nutraceutical excipients, including lactose variants, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, and high-purity BioHale sugars (sucrose, trehalose dihydrate). Products serve as fillers, binders, disintegrants, and stabilizers in oral solid dose, inhalation, biopharmaceutical, and nutraceutical formulations, sold directly to drug manufacturers.

Product overview

DFE Pharma is a global leader in pharmaceutical and nutraceutical excipient solutions, operating as a single unified product portfolio rather than a modular platform. The core offering centers on functional excipients—primarily lactose variants (including spray-dried, anhydrous, and granulated forms) and cellulose-based ingredients (microcrystalline cellulose, croscarmellose sodium, and sodium starch glycolate)—used as fillers, binders, disintegrants, and stabilizers across oral solid dosage, inhalation, and biopharmaceutical applications. The BioHale® sub-brand (comprising Sucrose and Trehalose Dihydrate) provides high-purity, low-endotoxin excipients specifically for biological drug formulations including vaccines. A 2026 Continuous Manufacturing Platform, developed in partnership with Gericke and hosted at the C2F Center of Excellence in Hyderabad, extends the portfolio into process optimization services for pharmaceutical manufacturers transitioning to continuous production methods.

Differentiator

Problem solved

Functional benefit

Brands

• BioHale: High-purity excipients portfolio for biological products including BioHale Sucrose and BioHale Trehalose Dihydrate, used in biologics formulations and COVID-19 vaccines
• Lactohale

Products and services

• Lactose Excipient Portfolio Comprehensive range of lactose variants used as fillers, binders, disintegrants, and stabilizers in oral solid dosage pharmaceutical and nutraceutical formulations.
• Cellulose and Starch Excipient Portfolio Comprehensive portfolio of cellulose products including microcrystalline cellulose (MCC), croscarmellose sodium, sodium starch glycolate, starches, and co-processed multifunctional excipients for pharmaceutical tablet and capsule formulations.
• BioHale Sucrose High-purity, low endotoxin sucrose excipient for stabilization of biological formulations in biopharmaceutical applications including parenteral, inhalation, oral, and ophthalmic administration routes. Conforms to F. Eur., USP-NF, JP, and ChP pharmacopeias.
• BioHale Trehalose Dihydrate High-purity, low endotoxin trehalose dihydrate excipient for stabilization of biological formulations in biopharmaceutical applications, conforming to F. Eur., USP-NF, JP, and ChP pharmacopeias.
• Inhalation Lactose (DPI Products) Lactose-based excipients optimized for dry powder inhalation (DPI) therapies, including Lactohale 300 and DPI blend products, designed as vehicles to ensure controlled release of active pharmaceutical ingredients to the lungs with customizable properties matched to specific device and molecule combinations.
• Continuous Manufacturing Platform Collaborative platform with Gericke enabling pharmaceutical companies to test formulation strategies and evaluate continuous manufacturing processes, featuring CM-ready excipients, a testing environment at the C2F Center of Excellence in Hyderabad, India, and regulatory alignment with ICH Q13 guidelines.

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• GerickecoreStrategic or Co-development Partner · 18 February 2026DFE Pharma launched a Continuous Manufacturing platform in collaboration with Gericke to support pharmaceutical companies in formulation development, process optimization, and lifecycle management of continuous manufacturing (CM) operations. The platform combines CM-ready excipients, a testing environment at DFE Pharma's C2F Center of Excellence in Hyderabad, India (featuring a Gericke Formulation Skid with modular dosing and mixing options in a non-GMP environment), and multidisciplinary expertise from both companies to enable data-driven decisions from early exploration through long-term operations, aligned with ICH Q13 regulatory guidelines.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Roquette: Roquette is a global leader in starch, polyols, and pharmaceutical excipients, including lactose, microcrystalline cellulose, and specialty binders—directly competing with DFE Pharma across OSD, biopharma, and nutraceutical dosage forms.
• Meggle: Meggle is a Germany-headquartered specialist in lactose-based pharmaceutical excipients for OSD and inhalation, overlapping directly with DFE Pharma's core lactose and Lactohale portfolios.
• JRS Pharma: JRS Pharma manufactures cellulose-based excipients (MCC, croscarmellose sodium) and binders/starches for OSD formulations, directly competing with DFE Pharma's cellulose and starch portfolio.
• Ashland: Ashland produces pharmaceutical excipients including coatings, binders, disintegrants, and specialty polymers for OSD and biopharma applications, directly competing with DFE's excipient portfolio.

Broad incumbents

• BASF: BASF's pharma solutions division supplies excipients, APIs, and intermediates globally, overlapping with DFE Pharma on functional excipients while offering a much wider chemistry and ingredient portfolio.
• Evonik: Evonik's specialty additives and pharma polymer businesses produce excipient and delivery ingredients serving OSD and parenteral applications, competing as a broader specialty chemicals incumbent.
• Kerry Group: Kerry's pharma and nutrition ingredients business offers excipients and functional ingredients for pharma and nutraceutical manufacturers, overlapping with DFE's nutraceutical and OSD portfolios as a broader ingredient platform.
• DuPont (now IFF Health & Biosciences): DuPont's Nutrition & Biosciences (now part of IFF) supplies pharmaceutical excipients including MCC and specialty ingredients, serving as a broader incumbent competing with DFE across multiple dosage forms.

Emerging players

• Ingredion: Ingredion supplies specialty starches and ingredient systems with growing pharma/nutraceutical applications, providing partial overlap with DFE's starch and cellulose-based excipient lines.

Regional players

• Shin-Etsu Chemical: Shin-Etsu supplies pharmaceutical excipients including MCC and coating polymers, primarily serving Japanese and Asian markets—an overlapping product portfolio with DFE but with regional concentration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCRBJWUlLc200YzcCTvy4CSw
• LinkedInlinkedin.com/company/dfe-pharma

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DFE Pharma